Selection of response criteria for clinical trials of sarcoma treatment.
about
Joint modeling tumor burden and time to event data in oncology trials.Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancerA phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.Rexin-G, a targeted genetic medicine for cancer.Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma.Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcomaImaging findings in craniofacial childhood rhabdomyosarcoma.Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.Tumor volume as an alternative response measurement for imatinib treated GIST patients.Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failureTherapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI.Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward(18)F-FDG PET in sarcoma treatment response imaging.Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer.Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).Evaluation of cancer treatment in the abdomen: Trends and advances.PET-CT imaging in pediatric oncology.New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.Uncertainties in RECIST as a measure of volume for lung nodules and liver tumors.Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.Semi-automated volumetric quantification of tumor necrosis in soft tissue sarcoma using contrast-enhanced MRI.Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma.Innovations in Clinical Trial Design in the Era of Molecular Profiling.Size-based clinical response evaluation is insufficient to assess clinical response of sarcomas treated with isolated limb perfusion with TNF-α and melphalan.Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity.Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma.
P2860
Q30837595-8E691C03-1F2B-47CD-98A3-233D2646AD17Q33771180-FF70110A-BFA3-45EE-806B-734E514391C8Q34094887-BCBB9A1E-7B39-487B-B05C-22259C4B552CQ34109646-68854D6C-C1EE-434A-8552-DC7C5EA4EB39Q34129461-3EF77E54-A53D-4E90-8847-94573D201A7DQ34138698-C01BFE5D-65C8-4F3A-B6E9-7092C618BBB5Q34176966-D4297BD0-5D14-4FD6-A9FA-EE4F0A8C59E3Q34356540-8EBAA33E-741B-4860-8A46-BA0C3719B6CCQ34469701-9ED510A3-379F-4A82-AEBD-37B7A3D64211Q34614365-8840A5D1-321B-483A-8A95-9BD7984343DAQ34978457-DF266DE1-D7B4-4153-B4D6-7BFC996CDBCDQ35001643-643A4956-4933-442A-AB4C-5F0430CC443AQ35148900-5230A841-DFC2-4638-B338-12A4E5086A77Q35214578-53010035-4487-4CD8-819C-0B320A6B2477Q36072962-49FEEA75-0AEA-4320-9243-DC8918A68177Q36337223-3D8F4248-230A-4302-8A52-94E0A095065FQ36406800-B5B4F659-5B70-467A-8073-3B375D470AA9Q36472317-66B4C1F3-4D0E-43E3-87DA-B3889419B24BQ36832118-90FFE90B-4ED1-49F5-8F66-3F7C10A4B291Q37337261-226BE3E7-643E-4240-A812-260F71EEB933Q37577930-9F64561E-359F-4093-A201-267206F8A665Q37621564-24D01A30-9DCA-455C-AF3E-026527476A73Q38055499-8D821711-E561-4057-9B2B-F696C33BC14BQ38265024-E6521F0E-122E-4FC7-8745-1F0E96405F45Q38777057-8092C521-EE54-482A-B4A8-E9CF1BFF673EQ39621244-DC2FA422-2ACF-44AC-AD11-2FE4BA6F5855Q41717674-BA208678-BCD2-4168-B1E7-21FF0DE3FA44Q41810446-0EEE0290-E7D9-43D8-A2B4-66D71726F7ABQ41963479-02E111C1-2C22-482E-824E-116E83DA4292Q45059047-00553A89-8FAE-4ED2-B447-15E669E8F776Q47308518-3E5BE1E9-1D65-490F-A4E2-61DF911288D0Q52890427-DA29690D-75FB-4C12-9612-A561B770AC36Q53464347-EA855FB8-F3A1-4F73-8A65-E962A75A36F2
P2860
Selection of response criteria for clinical trials of sarcoma treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Selection of response criteria for clinical trials of sarcoma treatment.
@en
Selection of response criteria for clinical trials of sarcoma treatment.
@nl
type
label
Selection of response criteria for clinical trials of sarcoma treatment.
@en
Selection of response criteria for clinical trials of sarcoma treatment.
@nl
prefLabel
Selection of response criteria for clinical trials of sarcoma treatment.
@en
Selection of response criteria for clinical trials of sarcoma treatment.
@nl
P2093
P1433
P1476
Selection of response criteria for clinical trials of sarcoma treatment.
@en
P2093
Laurence H Baker
Renzo Canetta
Robert S Benjamin
Scott M Schuetze
P356
10.1634/THEONCOLOGIST.13-S2-32
P478
13 Suppl 2
P577
2008-01-01T00:00:00Z